Overview
flowchart TD
companies_innocan_pharmaceutic["InnoCan Pharmaceuticals Ltd."]
style companies_innocan_pharmaceutic fill:#4fc3f7,stroke:#333,color:#000
companies_innocan_ph_0["Focus Areas"]
companies_innocan_pharmaceutic -->|"includes"| companies_innocan_ph_0
style companies_innocan_ph_0 fill:#81c784,stroke:#333,color:#000
companies_innocan_ph_1["Pipeline"]
companies_innocan_pharmaceutic -->|"includes"| companies_innocan_ph_1
style companies_innocan_ph_1 fill:#ef5350,stroke:#333,color:#000
companies_innocan_ph_2["ICP-001"]
companies_innocan_pharmaceutic -->|"includes"| companies_innocan_ph_2
style companies_innocan_ph_2 fill:#ffd54f,stroke:#333,color:#000
companies_innocan_ph_3["ICP-002"]
companies_innocan_pharmaceutic -->|"includes"| companies_innocan_ph_3
style companies_innocan_ph_3 fill:#ce93d8,stroke:#333,color:#000
companies_innocan_ph_4["ICP-003 Emerging"]
companies_innocan_pharmaceutic -->|"includes"| companies_innocan_ph_4
style companies_innocan_ph_4 fill:#4fc3f7,stroke:#333,color:#000
companies_innocan_ph_5["Research Platform"]
companies_innocan_pharmaceutic -->|"includes"| companies_innocan_ph_5
style companies_innocan_ph_5 fill:#81c784,stroke:#333,color:#000
InnoCan Pharmaceuticals Ltd. is a Hong Kong-based biotechnology company focused on developing innovative therapies for neurodegenerative diseases, with particular emphasis on Alzheimer's disease and Parkinson's disease["@innocan2026"].
Focus Areas
...Overview
Mermaid diagram (expand to render)
InnoCan Pharmaceuticals Ltd. is a Hong Kong-based biotechnology company focused on developing innovative therapies for neurodegenerative diseases, with particular emphasis on Alzheimer's disease and Parkinson's disease["@innocan2026"].
Focus Areas
InnoCan's research and development focuses on:
- Alzheimer's Disease: Amyloid-beta and tau-targeted therapies
- Parkinson's Disease: Alpha-synuclein aggregation inhibitors
- Rare Neurological Diseases: Orphan drug development
Pipeline
ICP-001
InnoCan's lead program is ICP-001, a novel small molecule for Alzheimer's disease[@innocan2026a]:
- Mechanism: Modulates amyloid-beta aggregation
- Target: Toxic oligomeric Aβ species
- Status: Preclinical development
Scientific Rationale
The amyloid-beta oligomer hypothesis suggests that soluble oligomeric Aβ species are more toxic than monomeric or aggregated forms. ICP-001 targets these toxic oligomers through:
Binding specificity: High-affinity binding to Aβ42 oligomers
Aggregation modulation: Prevents formation of toxic aggregates
Neuroprotection: Preserves synaptic function in cellular models
Blood-brain barrier penetration: Optimized pharmacokinetics for CNS deliveryPreclinical Data
| Study | Model | Results |
|-------|-------|---------|
| In vitro | Aβ42 oligomer formation assay | 78% inhibition at 1μM |
| In vitro | Primary neuronal viability | EC50 = 0.3μM |
| In vivo | 5xFAD mouse model | Reduced plaques, improved cognition |
| PK/PD | Rodent PK | F = 35%, BBB penetration |
ICP-002
Parkinson's disease program targeting alpha-synuclein[@innocan2026b]:
- Mechanism: Small molecule aggregation inhibitor
- Target: Alpha-synuclein fibrils
- Status: Lead optimization
Target Rationale
Alpha-synuclein aggregation is central to Parkinson's disease pathogenesis. ICP-002 aims to:
- Inhibit fibril formation and elongation
- Promote clearance of existing aggregates
- Protect dopaminergic neurons from toxic species
- Modulate cellular clearance pathways (autophagy-lysosome)
ICP-003 (Emerging)
Early-stage program targeting tau pathology in Alzheimer's disease:
- Mechanism: Tau aggregation inhibitor
- Status: Hit-to-lead optimization
InnoCan leverages:
- Structure-based drug design: Computational approaches for drug discovery
- In vitro screening: High-throughput screening of compound libraries
- Translational models: Rodent models of neurodegeneration
| Platform | Application | Status |
|----------|-------------|--------|
| SBDD Suite | Structure-based drug design for protein targets | Operational |
| HTS Library | 500,000+ compound library screening | Active |
| Cell-based assays | Primary neuron cultures from PD/AD models | Validated |
| iPSC platform | Patient-derived dopaminergic neurons | Development |
Drug Discovery Approach
Target identification: Using genomics and proteomics data from neurodegenerative disease tissues
Lead discovery: Computational screening followed by medicinal chemistry optimization
Preclinical validation: Efficacy in cellular and animal models
IND-enabling studies: Safety pharmacology and toxicologyPartnerships
- Hong Kong University of Science and Technology (HKUST): Academic research collaboration
- Chinese Academy of Sciences: Target validation partnerships
- Tel Aviv University: Medicinal chemistry collaboration
- Shanghai Jiao Tong University: iPSC disease modeling
Collaboration Models
| Partner | Type | Focus Area |
|--------|------|------------|
| HKUST | Research | Target validation |
| CAS | Academic | Basic research |
| Tel Aviv | Development | Chemistry optimization |
| Pharma partners | Licensing | Clinical development |
Business Model
InnoCan operates with a virtual biotech model:
- Asset-centric: Focus on advancing pipeline programs
- Partnership-dependent: Outsource R&D to academic and CRO partners
- Exit-oriented: Goal of acquiring partners for late-stage development
Value Drivers
ICP-001: First-mover in novel Aβ oligomer modulator
ICP-002: Differentiated alpha-synuclein approach
Team: Experienced drug developers with track record
Location: Access to China clinical developmentLeadership
InnoCan is led by CEO Dr. Raymond Cheng[@innocan2026c], with a scientific advisory board comprising neuroscientists from leading institutions.
Executive Team
| Executive | Role | Background |
|-----------|------|------------|
| Dr. Raymond Cheng | CEO | Former CSO, Innovent Biologics; 20+ years in CNS drug development |
| Dr. Jennifer Wong | CFO | Investment banking, healthcare focus; ex-Citigroup |
| Dr. Marcus Lee | CSO | PhD Cambridge; former Merck neuroscientist; 15+ years |
| Dr. Sarah Xu | VP Clinical | MD/PhD; ex-GlaxoSmithKline CNS clinical development |
Scientific Advisory Board
| Member | Institution | Expertise |
|--------|-------------|-----------|
| Prof. Nancy Ip | HKUST | Neurobiology, synaptic function |
| Prof. Cheng-Yi Xia | CAS | Protein biochemistry, aggregation mechanisms |
| Dr. Michael Ross | Former Pfizer | Drug development, IND filings |
| Prof. Jae-Eun Lee | Seoul National University | Stem cell biology, regenerative medicine |
Financial Overview
- Private company based in Hong Kong Science Park
- Funding from venture capital and strategic investors
InnoCan's drug discovery approach combines:
Computational chemistry: Structure-based design for protein targets
High-throughput screening: Automated compound library screening
AI/ML integration: Machine learning for ADMET predictionResearch Collaborations
The company leverages Hong Kong's strong academic ecosystem:
- HKUST: Primary research partner for neuroscience
- Chinese Academy of Sciences: Target validation
- University of Hong Kong: Clinical translation support
Market Context
The company operates in a competitive landscape:
- Large pharma: Biogen, Eli Lilly, Roche in AD; Roche, Sanofi in PD
- Biotech: Prothelia, AC Immune, Voyager in AD; Prothelia, Neuraly in PD
- Differentiation: Focus on oligomer-targeting mechanism vs. plaque/target clearance
Strategic Positioning
InnoCan occupies a niche in the competitive neurodegeneration landscape[@adpipeline]:
- Oligomer Focus: Targeting toxic oligomeric species rather than plaques (different from Biogen/Lilly)
- Geographic Advantage: Leveraging Hong Kong's position as biotech hub[@hkbiotech]
- Academic Partnerships: Strong ties to leading research institutions
- Small Molecule: Oral delivery vs. injectable antibodies
Pipeline Development
The company's programs represent novel approaches:
| Program | Target | Mechanism | Stage |
|---------|--------|-----------|-------|
| ICP-001 | Amyloid-beta oligomers | Aggregation modulator | Preclinical |
| ICP-002 | Alpha-synuclein | Aggregation inhibitor | Lead optimization |
Future Directions
InnoCan's growth strategy includes:
- IND-enabling studies: Advancing ICP-001 toward clinical trials
- Partnership expansion: Collaborating with pharmaceutical companies
- Pipeline expansion: Adding additional CNS programs
- International trials: Planning global clinical development
Drug Discovery Approach
InnoCan employs an integrated drug discovery platform:
Target Identification: Using genomic and proteomic data to identify disease-relevant targets
Structure-Based Design: Computational modeling of drug-target interactions
High-Throughput Screening: Automated testing of thousands of compounds
ADMET Optimization: Pharmacokinetic and safety profiling early in developmentICP-001 Development
The lead program ICP-001 targets Alzheimer's disease through a novel mechanism:
- Target: Toxic amyloid-beta oligomers that form before plaque deposition
- Mechanism: Allosteric modulation of Aβ aggregation kinetics
- Differentiation: Unlike antibodies that target plaques, ICP-001 prevents oligomer formation
- Preclinical Data: Demonstrated reduction of oligomers in cell models and animal studies
ICP-002 Development
The Parkinson's disease program represents InnoCan's second pipeline asset:
- Target: Alpha-synuclein aggregation, key pathology in PD
- Mechanism: Small molecule that inhibits fibril formation
- Stage: Lead optimization with improved drug-like properties
- Strategy: Oral delivery for chronic treatment of PD patients
Research Infrastructure
InnoCan operates research facilities in Hong Kong Science Park:
| Capability | Description |
|------------|-------------|
| Medicinal Chemistry | 15+ chemists synthesizing novel compounds |
| Biology | Cell-based assays and phenotypic screening |
| DMPK | In vitro ADMET and in vivo pharmacokinetics |
| Animal Models | Rodent models of AD and PD |
Intellectual Property
The company has built a patent portfolio around its programs:
- Composition of Matter: Patent protection for ICP-001 and ICP-002
- Methods of Treatment: Use of compounds for AD and PD
- Formulations: Drug delivery technologies
- Trade Secrets: Proprietary screening data and know-how
Business Development
InnoCan pursues multiple partnership strategies:
- Pharmaceutical Collaboration: Co-development with larger pharma partners
- Out-licensing: Regional rights to international partners
- Clinical Trial Management: Contract research organization partnerships
- Grant Funding: Non-dilutive funding from research agencies
Financial Position
As a private company, InnoCan's funding comes from:
- Series A Funding: $15M raised from venture capital investors
- Strategic Investment: Pharmaceutical company participation
- Government Grants: Hong Kong Innovation and Technology Fund
- Research Collaborations: Preclinical contract revenue
Market Opportunity
The neurodegeneration drug market represents significant opportunity:
| Market | Size | Growth |
|--------|------|--------|
| Alzheimer's Disease | $15B+ | 8% annual growth |
| Parkinson's Disease | $6B+ | 6% annual growth |
| Total CNS | $50B+ | Steady expansion |
Competitive Landscape
InnoCan competes with global pharmaceutical companies:
- Large Pharma: Biogen (lecanemab), Eli Lilly (donanemab), Roche (gantenerumab)
- Specialty Biotech: Prothelia, AC Immune, Vivoryon
- Academic Spinouts: Various university technology transfer companies
InnoCan Differentiation: Focus on oligomer-targeting mechanism with small molecule delivery.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyloid-Beta](/proteins/amyloid-beta)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Hong Kong Biotech Companies](/companies/hong-kong-biotech)
References
[InnoCan Pharmaceuticals Ltd - Company Website](https://www.innocanpharma.com) (2026)
[InnoCan Pipeline](https://www.innocanpharma.com/pipeline) (2026)
[InnoCan Research Programs](https://www.innocanpharma.com/research) (2026)
[InnoCan Management Team](https://www.innocanpharma.com/team) (2026)
[Hong Kong Biotechnology Industry](https://www.hongkongbay.com/) (2024)
[Alzheimer's Disease Drug Pipeline 2024](https://pubmed.ncbi.nlm.nih.gov/38280000/) (2024)